IP Library › Granted Patent US 12,527,850
Granted Patent B2
US 12,527,850 · App. 17/262,935 · Granted Jan 20, 2026

Cancer vaccines for breast cancer

Inventor: Ronald Hans Anton Plasterk (Amsterdam, NL)
Assignee: CureVac Netherlands B.V.
A61K39/0011
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,527,850
App. No.
17/262,935
Granted
Jan 20, 2026
Kind
B2
Abstract

The invention relates to the field of cancer, in particular breast cancer. In particular it relates to the field of immune system directed approaches for tumor reduction and control. Some aspects of the invention relate to vaccines, vaccinations and other means of stimulating an antigen specific immune response against a tumor in individuals. Such vaccines comprise neoantigens resulting from frameshift mutations that bring out-of-frame sequences of the GATA3, CDH1, MAP3K1, RUNX1, and TP53 genes in-frame. Such vaccines are also useful for ‘off the shelf’ use.

Claims (26)

1 . A vaccine or collection of vaccines for treating breast cancer comprising:

(i) a first nucleic acid molecule encoding a first polypeptide, the first polypeptide having an amino acid sequence at least 90% identical to SEQ ID NO:19, wherein the first nucleic acid molecule is comprised in a vector; and

(ii) a second polypeptide, or a nucleic acid molecule encoding the second polypeptide, having an amino acid sequence at least 90% identical to SEQ ID NO:17, 18, 20, 21, 22 or 23, or an amino acid sequence comprising at least 10 consecutive amino acids of SEQ ID NO:17, 18, 20, 21, 22 or 23.

2 . The vaccine or collection of vaccines of claim 1 , wherein said vector is a viral vector.

3 . The vaccine or collection of vaccines of claim 1 , further comprising a pharmaceutically acceptable excipient, an adjuvant, or a therapeutic agent.

4 . The vaccine or collection of vaccines of claim 3 , wherein the therapeutic agent is a checkpoint inhibitor, a chemotherapeutic agent, or an antibody.

5 . The vaccine or collection of vaccines of claim 3 , further comprising an immune-effective amount of adjuvant.

6 . A method for providing a vaccine for immunizing a patient against a cancer in said patient comprising determining the sequence of TP53 in cancer cells of said cancer and when the determined sequence comprises a frameshift mutation that produces a neoantigen of SEQ ID NO:19 or a fragment thereof, providing a vaccine selected from the vaccine or collection of vaccines of claim 1 .

7 . A method of treating an individual for breast cancer, the method comprising administering to the individual in need thereof a vaccine selected from a vaccine or collection of vaccines comprising:

(i) a first polypeptide, or a nucleic acid molecule encoding the first polypeptide, having an amino acid sequence at least 90% identical to SEQ ID NO:19; and

(ii) a second polypeptide, or a nucleic acid molecule encoding the second polypeptide, having an amino acid sequence at least 90% identical to SEQ ID NO:17, 18, 20, 21, 22 or 23, or an amino acid sequence comprising at least 10 consecutive amino acids of SEQ ID NO:17, 18, 20, 21, 22 or 23.

8 . The vaccine or collection of vaccines of claim 1 , comprising a first nucleic acid molecule encoding the first polypeptide, wherein:

(a) the first nucleic acid molecule further comprises a sequence encoding the second polypeptide; or

(b) the vaccine or collection of vaccines further comprises a second nucleic acid molecule encoding the second polypeptide.

9 . The vaccine or collection of vaccines of claim 8 , wherein the first nucleic acid molecule is an RNA molecule.

10 . The vaccine or collection of vaccines of claim 9 , wherein the RNA molecule is an mRNA.

11 . The vaccine or collection of vaccines of claim 9 , wherein the RNA molecule is an RNA replicon.

12 . The vaccine or collection of vaccines of claim 8 , wherein the second nucleic acid molecule is an RNA molecule.

13 . The vaccine or collection of vaccines of claim 12 , wherein the RNA molecule is an mRNA.

14 . The vaccine or collection of vaccines of claim 12 , wherein the RNA molecule is an RNA replicon.

15 . The method of treating of claim 7 , wherein the first nucleic acid molecule is an RNA molecule.

16 . The method of treating of claim 15 , wherein the RNA molecule is an mRNA.

17 . The method of treating of claim 15 , wherein the RNA molecule is an RNA replicon.

18 . The method of treating of claim 7 , wherein the second nucleic acid molecule is an RNA molecule.

19 . The method of treating of claim 18 , wherein the RNA molecule is an mRNA.

20 . The method of treating of claim 18 , wherein the RNA molecule is an RNA replicon.

Assignments (2)
CHANGE OF NAME Recorded Jul 20, 2022
From: FRAME PHARMACEUTICALS B.V.
To: CUREVAC NETHERLANDS B.V.
Reel/Frame 060765/0365 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 11, 2021
From: PLASTERK, RONALD HANS ANTON
To: FRAME PHARMACEUTICALS B.V.
Reel/Frame 055229/0001 →
Priority Claims (3)
NL 2021400 · Jul 26, 2018 · national
NL 2022447 · Jan 24, 2019 · national
EP 19167595 · Apr 5, 2019 · regional
Continuity (1)
Related Publication 20210162032A1 · Jun 3, 2021
References Cited (77)
US 20070083334A1 · Mintz et al. · 2007 [cited by applicant]
US 20160069895A1 · Delamarre et al. · 2016 [cited by applicant]
US 20160101170A1 · Hacohen et al. · 2016 [cited by applicant]
US 20170028043A1 · Benz et al. · 2017 [cited by applicant]
US 20170028044A1 · Soon-Shiong et al. · 2017 [cited by applicant]
US 20170032082A1 · Nguyen et al. · 2017 [cited by applicant]
US 20170032103A1 · Nguyen et al. · 2017 [cited by applicant]
US 20170202939A1 · Carreno et al. · 2017 [cited by applicant]
US 20170312351A1 · Niazi et al. · 2017 [cited by applicant]
US 20180064793A1 · Mcgranahan et al. · 2018 [cited by applicant]
US 20180078624A1 · Zhou et al. · 2018 [cited by applicant]
US 20180078625A1 · Moon et al. · 2018 [cited by applicant]
US 20180318409A1 · Valiante et al. · 2018 [cited by applicant]
US 20180340944A1 · Han et al. · 2018 [cited by applicant]
US 20190022202A1 · Granum et al. · 2019 [cited by applicant]
US 20190030147A1 · Artomov et al. · 2019 [cited by applicant]
US 20190060428A1 · Fritsch · 2019 [cited by applicant]
US 20190083593A1 · Sahin et al. · 2019 [cited by applicant]
US 20190091316A1 · Soon-Shiong et al. · 2019 [cited by applicant]
JP 2015188400A · 2015 [cited by applicant]
WO 1995032731A2 · 1995 [cited by applicant]
WO 20040111075A2 · 2004 [cited by applicant]
WO 2011143656A2 · 2011 [cited by applicant]
WO 2012159754A2 · 2012 [cited by applicant]
WO 2014168874A2 · 2014 [cited by applicant]
WO 2015095811A2 · 2015 [cited by applicant]
WO 2016040900A1 · 2016 [cited by applicant]
WO 2016154544A1 · 2016 [cited by applicant]
WO 2016172722A1 · 2016 [cited by applicant]
WO 2016187508A2 · 2016 [cited by applicant]
WO 2016201049A2 · 2016 [cited by applicant]
WO 2017020026A1 · 2017 [cited by applicant]
WO 2017106638A1 · 2017 [cited by applicant]
WO 2017118702A1 · 2017 [cited by applicant]
WO 2017139694A1 · 2017 [cited by applicant]
WO 2017173321A1 · 2017 [cited by applicant]
WO 2017177207A1 · 2017 [cited by applicant]
WO 2017194170A1 · 2017 [cited by applicant]
WO 2017223085A2 · 2017 [cited by applicant]
WO 2018015433A2 · 2018 [cited by applicant]
WO 2018026896A1 · 2018 [cited by applicant]
WO 2018102584A1 · 2018 [cited by applicant]
WO 2018136664A1 · 2018 [cited by applicant]
WO 2018144082A1 · 2018 [cited by applicant]
WO 2018144775A1 · 2018 [cited by applicant]
WO 2018195357A1 · 2018 [cited by applicant]
WO 2018200389A1 · 2018 [cited by applicant]
WO 2018213803A1 · 2018 [cited by applicant]
WO 2018223092A1 · 2018 [cited by applicant]
WO 2018223094A1 · 2018 [cited by applicant]
WO 2018224405A1 · 2018 [cited by applicant]
WO 2018234516A2 · 2018 [cited by applicant]
WO 2019008364A1 · 2019 [cited by applicant]
WO 2019012082A1 · 2019 [cited by applicant]
WO 2019036043A2 · 2019 [cited by applicant]
WO 2019126186A1 · 2019 [cited by applicant]
Duffy et al. (“Mutant p53 in breast cancer: potential as a therapeutic target and biomarker”; 2018; Breast Cancer Res Treat 170, 213-219) (Year: 2018). [cited by examiner]
Carbone et al. (“Immunization with mutant p53- and K-ras-derived peptides in cancer patients: immune response and clinical outcome”; 2015; Journal of Clinical Oncology, 23(22):5099-5107) (Year: 2015). [cited by examiner]
Cuzick (“Preventive therapy for cancer”, The Lancet Oncology, vol. 18, Issue 8,2017, pp. 472-482) (Year: 2017). [cited by examiner]
Orfanelli, T. et al., “Shared tumor antigens in uterine cancers with microsatellite instability: Putative targets for immunotherapeutic approaches”, Gynecologic Oncology, Jun. 2019, 154(1):91, DOI: 10.1016/j.ygyno.2019.… [cited by applicant]
Roudko, V. et al., “Widespread immunogenic poly-epitope frameshift mutations in microsatellite unstable tumors”, bioRxiv 2019; doi: https://doi.org/10.1101/662262; pp. 1-53. [cited by applicant]
Hartmaier, R. et al., “Genomic analysis of 63,220 tumors reveals insights into tumor uniqueness and targeted cancer immunotherapy strategies”, Genome Medicine, BioMed Central, vol. 9, Article No. 16 (2017), pp. 1-9. [cited by applicant]
Batista, M.T. et al., “Abstract 1463: FAST vaccines based on frameshift neoantigens may have advantages over personal vaccines”, Proceedings of American Association for Cancer Research Annual Meeting 2019, Mar. 29, 2019… [cited by applicant]
Zhang, J. et al., “Using Frameshift Peptide Arrays for Cancer Neo-Antigens Screening”, Scientific Reports, vol. 8, No. 1, (2018), pp. 1-10. [cited by applicant]
Koster, J. et al., “A library of Neo Open Reading Frame peptides (NOPs) as a sustainable resource of common neoantigens in up to 50% of cancer patients”, Scientific Reports, 2019, vol. 9, Nr: 1. [cited by applicant]
Schwitalle, Y. et al., “Immunogenic peptides generated by frameshift mutations in DNA mismatch repair-deficient cancer cells”, Cancer Immun. 2004 Academy of Cancer Immunology, CH-ISSN 1424-9734, vol. 4, Nr:1, pp. 1-10. [cited by applicant]
Luhui, S. et al., “Abstract 469: Progress towards developing a universal, prophylactic cancer vaccine.”, American Association for Cancer Research; vol. 73, No. 8, Suppl. Apr. 1, 2013 (Apr. 1, 2013). [cited by applicant]
Linnebacher et al., “Frameshift peptide-derived T-cell epitopes: a source of novel tumor-specific antigens”, Int. J. Cancer: 93, pp. 6-11 (2001). [cited by applicant]
Schumacher et al., “Neoantigens in cancer immunotherapy”, Science, 2015, vol. 348, Issue 6230, pp. 69-74. [cited by applicant]
Rahma et al., “A pilot clinical trial testing mutant von Hippel-Lindau peptide as a novel immune therapy in metastatic Renal Cell Carcinoma”, Journal of Translational Medicine, 2010, 8:8, 9 pages. [cited by applicant]
Hacohen et al., “Getting Personal with Neoantigen-Based Therapeutic Cancer Vaccines”, Cancer Immunol. Res., Jul. 2013; 1(1): 11-15, pp. 1-8. [cited by applicant]
Ito et al., “Cancer Neoantigens: A Promising Source of Immunogens for Cancer Immunotherapy”, J Clin Cell Immunol 2015, 6:2, pp. 1-7. [cited by applicant]
Tomczak et al., “The Cancer Genome Atlas (TCGA): an immeasurable source of knowledge”, Contemp Oncol (Pozn). 2015, 19 (1A): A68-A77. [cited by applicant]
The Cancer Genome Atlas Research Network. “Comprehensive molecular characterization of clear cell renal cell carcinoma”, Nature (2013), 499, pp. 43-49. [cited by applicant]
Pavlopoulou et al., “Human cancer databases (review)”, Oncology Reports, 33: pp. 3-18, 2015. [cited by applicant]
Rammensee, H-G et al., “Cancer Vaccines: Some Basic Considerations”, Genomic and Personalized Medicine, 2009, Elsevier, pp. 573-589. [cited by applicant]
Rajasagi, M. et al., “Systematic identification of personal tumor-specific neoantigens in chronic lymphocytic leukemia”, Blood, 2014, ISSN 0006-4971, vol. 124, Nr: 3, pp. 453-462. [cited by applicant]